Guillain-Barre Syndrome Market Size, Share, Growth and Industry Forecast
The Guillain-Barre Syndrome Market is witnessing steady expansion as awareness, diagnostic capabilities, and treatment access improve worldwide. According to Market Research Future, the market was valued at USD 820.5 million in 2025 and is projected to reach USD 1,490.7 million by 2035, registering a CAGR of 6.2%.
Guillain-Barré syndrome (GBS) is a rare neurological disorder in which the immune system attacks peripheral nerves. Increasing recognition of post-infectious neurological complications and improvements in specialist diagnosis are contributing to demand for effective treatment options.
Intravenous immunoglobulin (IVIG) remains a major treatment category, while plasma exchange continues to be used for severe cases. The development of complement inhibitors and other targeted biologics is creating new opportunities for disease-specific treatment approaches.
Regional growth is also important. North America represented approximately 47.1% of the market in 2025, supported by established healthcare infrastructure, specialist neurology networks, and favorable reimbursement. Asia-Pacific is expected to be the fastest-growing region, with a projected CAGR of 9.1% through 2035.
Overall, advances in diagnostics, emerging biologic therapies, improved treatment accessibility, and investments in neurological healthcare are expected to support continued growth in the global GBS market.